CompletedPhase 1NCT01932528
An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males
Studying Carcinoid syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Lexicon Pharmaceuticals
- Principal Investigator
- Doug Fleming, MDLexicon Pharmaceuticals, Inc.
- Intervention
- 500 mg [14C]-LX1606(drug)
- Enrollment
- 8 enrolled
- Eligibility
- 30-65 years · MALE
- Timeline
- 2013
Study locations (1)
- Lexicon Investigational Site, Nottingham, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01932528 on ClinicalTrials.govOther trials for Carcinoid syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07087054Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine RegimenCrinetics Pharmaceuticals Inc.
- RECRUITINGNCT05756608Fibrosis in Chronic and Delayed Myocardial InfarctionUniversity of Edinburgh
- ACTIVE NOT RECRUITINGNANCT05064514Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart DiseaseQueen Mary University of London
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT04993261An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid TumorsM.D. Anderson Cancer Center